Search Result
Results for "
block polymers
" in MedChemExpress (MCE) Product Catalog:
70
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-Y0479
-
-
-
- HY-W040233
-
|
Sodium L-lactate
|
Others
|
Others
Cancer
|
|
Sodium (S)-2-hydroxypropanoate (Sodium L-lactate) is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid .
|
-
-
- HY-W040233B
-
|
Sodium L-lactate (purity≥90%)
|
Others
|
Others
|
|
Sodium (S)-2-hydroxypropanoate (Sodium L-lactate) (purity≥90%) is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid .
|
-
-
- HY-128711
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F) .
|
-
-
- HY-161338
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin polymerization-IN-61 (Compound 9a) is a tubulin polymerization inhibitor. Tubulin polymerization-IN-61 destroys the microtubule skeleton, blocks the cell cycle in G2/M phase, induces Apoptosis, and inhibits cancer cell migration and colony formation. Tubulin polymerization-IN-61 shows antitumor activity in vivo against 4T1 xenograft model .
|
-
-
- HY-D1005A25
-
|
PEG-PPG-PEG, 5750 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 403 P123 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 5750. Poloxamer 403 P123 exhibits muscular toxicity .
|
-
-
- HY-D1005A18
-
|
PEG-PPG-PEG, 13000 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 288 F98 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 13000. Poloxamer 288 F98 reduces the aggregation of red blood cells .
|
-
-
- HY-155754
-
|
|
ATP Synthase
|
Others
|
|
3’-Acetate-ATP, an ATP analogue, is ATP acetylation product with an maxima uv absorption at 259 nm in water at neutral pH. 3’-Acetate-ATP exerts a blocking effect on nucleic acid polymerization .
|
-
-
- HY-D1005A14
-
|
PEG-PPG-PEG, 6600 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 217 F77 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 6600. Poloxamer 217 F77 inhibits proliferation of human lymphocyte cell IIBR1 .
|
-
-
- HY-Y0479R
-
|
|
Bacterial
Endogenous Metabolite
Antibiotic
|
Infection
|
|
L-Lactic acid (Standard) is the analytical standard of L-Lactic acid. This product is intended for research and analytical applications. L-Lactic acid is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid.
|
-
-
- HY-W250580
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Dimethicone is an orally active biochemical assay reagents consisting of a fully methylated linear siloxane polymer whose ends are blocked by trimethylsiloxane units. Dimethicone can lubricate hair and physically block the respiratory system of lice to remove lice. Dimethicone has potential applications in cosmetics and daily cleaning products .
|
-
-
- HY-16928
-
Cytochalasin B
Maximum Cited Publications
29 Publications Verification
Phomin
|
Arp2/3 Complex
|
Cancer
|
|
Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of actin filaments, disrupting the formation of actin polymers, with Kd value of 1.4-2.2 nM for F-actin. Cytochalasin B blocks cell migration.
|
-
-
- HY-Y0479S3
-
-
-
- HY-D1005A23
-
|
PEG-PPG-PEG, 4400 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 401 L121 is block polymer of polyoxyethylene and polyoxypropylene. Poloxamer 401 L121 is utilized as lymphotrophic particles in nanoparticle engineering, as inhibitor of multidrug resistance and adjuvant activities or as surfactants and emulsifying agents in cosmetics .
|
-
-
- HY-D1005A1
-
|
PEG-PPG-PEG, 1100 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 101 L31 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1100. Poloxamer 101 L31 forms hydrogel, that is utilized as surfactants and emulsifying agents. Poloxamer 101 L31 induces slight alveolitis .
|
-
-
- HY-D1005A11
-
|
PEG-PPG-PEG, 3400 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 185 P65 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 3400. Poloxamer 185 P65 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
-
- HY-D1005A12
-
|
PEG-PPG-PEG, 2750 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 212 L72 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2750. Poloxamer 212 L72 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
-
- HY-D1005A13
-
|
PEG-PPG-PEG, 4150 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 215 P75 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 4150. Poloxamer 215 P75 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
-
- HY-D1005A15
-
|
PEG-PPG-PEG, 4200 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 234 P84 is is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 4200. Poloxamer 234 P84 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
-
- HY-D1005A2
-
|
PEG-PPG-PEG, 1900 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 105 L35 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1900. Poloxamer 105 L35 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
-
- HY-D1005A20
-
|
PEG-PPG-PEG, 5900 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 334 P104 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 5900. Poloxamer 334 P104 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
-
- HY-D1005A5
-
|
PEG-PPG-PEG, 1850 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 123 L43 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1850. Poloxamer 123 L43 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
-
- HY-D1005A7
-
|
PEG-PPG-PEG, 2400 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 125 L45 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2400. Poloxamer 125 L45 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
-
- HY-15892
-
CK-636
1 Publications Verification
CK-0944636
|
Arp2/3 Complex
|
Inflammation/Immunology
Cancer
|
|
CK-636 is a cell permeable inhibitor of Arp2/3 complex, that could inhibit actin polymerization, with IC50 values of 4 μM, 24 μM and 32 μM for human, fission yeast and bovine, respectively. CK636 blocks cell migration.
|
-
-
- HY-W013827
-
|
1,4:3,6-Dianhydromannitol
|
Biochemical Assay Reagents
|
Others
|
|
Isomannide (1,4:3,6-Dianhydromannitol) is a common intermediate compound that is a derivative of Isosorbide. Isomannide may be used as monomers and building blocks in novel polymers and functional materials, novel organic solvents, medical and pharmaceutical applications, and even as a fuel or fuel additive .
|
-
-
- HY-167342
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG4000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG4000-PLLA5000 can be used in drug delivery research .
|
-
-
- HY-167343
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG3000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG3000-PLLA5000 can be used in drug delivery research .
|
-
-
- HY-167344
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG2000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG2000-PLLA5000 can be used in drug delivery research .
|
-
-
- HY-167345
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG1000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG1000-PLLA5000 can be used in drug delivery research .
|
-
-
- HY-167346
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG8000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG8000-PLLA4000 can be used in drug delivery research .
|
-
-
- HY-167347
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG6000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG6000-PLLA4000 can be used in drug delivery research .
|
-
-
- HY-167348
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG4000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG4000-PLLA4000 can be used in drug delivery research .
|
-
-
- HY-167349
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG3000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG3000-PLLA4000 can be used in drug delivery research .
|
-
-
- HY-167350
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG2000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG2000-PLLA4000 can be used in drug delivery research .
|
-
-
- HY-167351
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA4000-PEG1000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG1000-PLLA4000 can be used in drug delivery research .
|
-
-
- HY-167352
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG8000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG8000-PLLA3000 can be used in drug delivery research .
|
-
-
- HY-167353
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG6000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG6000-PLLA3000 can be used in drug delivery research .
|
-
-
- HY-167354
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG4000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG4000-PLLA3000 can be used in drug delivery research .
|
-
-
- HY-167355
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG3000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG3000-PLLA3000 can be used in drug delivery research .
|
-
-
- HY-167356
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG2000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG2000-PLLA3000 can be used in drug delivery research .
|
-
-
- HY-167357
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA3000-PEG1000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG1000-PLLA3000 can be used in drug delivery research .
|
-
-
- HY-167358
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG8000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG8000-PLLA2000 can be used in drug delivery research .
|
-
-
- HY-167359
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG6000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG6000-PLLA2000 can be used in drug delivery research .
|
-
-
- HY-167360
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG4000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG4000-PLLA2000 can be used in drug delivery research .
|
-
-
- HY-167361
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG3000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG3000-PLLA2000 can be used in drug delivery research .
|
-
-
- HY-167362
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG2000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG2000-PLLA2000 can be used in drug delivery research .
|
-
-
- HY-167363
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA2000-PEG1000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG1000-PLLA2000 can be used in drug delivery research .
|
-
-
- HY-167364
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG8000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG8000-PLLA1000 can be used in drug delivery research .
|
-
-
- HY-167365
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG6000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG6000-PLLA1000 can be used in drug delivery research .
|
-
-
- HY-167366
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG4000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG4000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167367
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG3000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG3000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167368
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG2000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG2000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167369
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA1000-PEG1000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG1000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167119
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG8000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG8000-PLLA5000 can be used in drug delivery research .
|
-
- HY-167140
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA6000-PEG8000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG8000-PLLA6000 can be used in drug delivery research .
|
-
- HY-167137
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA6000-PEG6000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG6000-PLLA6000 can be used in drug delivery research .
|
-
- HY-167126
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA6000-PEG3000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG3000-PLLA6000 can be used in drug delivery research .
|
-
- HY-167128
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA8000-PEG8000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG8000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167130
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA8000-PEG6000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG6000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167136
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA8000-PEG3000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG3000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167134
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA8000-PEG4000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG4000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167132
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA6000-PEG4000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG4000-PLLA6000 can be used in drug delivery research .
|
-
- HY-167138
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA8000-PEG2000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG2000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167139
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA8000-PEG1000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG1000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167120
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA6000-PEG1000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG1000-PLLA6000 can be used in drug delivery research .
|
-
- HY-167118
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA5000-PEG6000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG6000-PLLA5000 can be used in drug delivery research .
|
-
- HY-167124
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PLLA6000-PEG2000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG2000-PLLA6000 can be used in drug delivery research .
|
-
- HY-16929
-
|
LAT-A
|
Arp2/3 Complex
|
Cancer
|
|
Latrunculin A (LAT-A), found in the red sea sponge Latrunculia magnifica, is a G-actin polymerization inhibitor. Latrunculin A binds to actin monomers and inhibits polymerization of actin with Kds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively. Latrunculin A has effective anti-metastatic properties for cancer research. Latrunculin A blocks cell migration .
|
-
- HY-156403
-
|
|
Topoisomerase
|
Cancer
|
|
AuM1Phe, an N-Heterocyclic carbene (NHC) metal complexe, blocks the human topoisomerase I activity and actin polymerization reaction. AuM1Phe affects the growth of MDA-MB-231 breast cancer cells, with an IC50 value of 1.2 μM .
|
-
- HY-122185
-
|
|
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
Anticancer agent 211 (AK301) can inhibit tubulin polymerization. Anticancer agent 211 can block the division of human colon cancer cells. Anticancer agent 211 can increase the sensitivity of human colon cancer cells to apoptotic ligands and promote cell apoptosis .
|
-
- HY-D1005A16
-
|
PEG-PPG-PEG, 4600 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 235 P85 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 4600. Poloxamer 235 P85 exhibits acute and subchronic toxicity in albino rats with an oral LD50 of >34.6 g/kg. Poloxamer 235 P85 induces ocular irritation in rabbits .
|
-
- HY-W040233R
-
|
|
Others
|
Others
Cancer
|
|
Sodium (S)-2-hydroxypropanoate (Standard) is the analytical standard of Sodium (S)-2-hydroxypropanoate. This product is intended for research and analytical applications. Sodium (S)-2-hydroxypropanoate (Sodium L-lactate) is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid .
|
-
- HY-D1005A17
-
|
PEG-PPG-PEG, 11400 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 238 F88 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 11400. Poloxamer 238 F88 reduces the aggregation of red blood cells. Poloxamer 238 F88 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A22
-
|
PEG-PPG-PEG, 14600 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 338 F108 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 14600. Poloxamer 338 F108 reduces the aggregation of red blood cells, inhibits proliferation of human lymphocyte cell IIBR1. Poloxamer 338 F108 exhibits short-term and subchronic toxicity in rats .
|
-
- HY-155902B
-
|
Maleimide-PEG-Hydroxy (MW 1000)
|
Biochemical Assay Reagents
|
Others
|
|
Mal-PEG-OH (MW 1000) was used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.
|
-
- HY-125527
-
|
RvD1
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages .
|
-
- HY-155902
-
|
Maleimide-PEG-Hydroxy (MW 5000)
|
Biochemical Assay Reagents
|
Others
|
|
Mal-PEG-OH (MW 5000) can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.
|
-
- HY-155902A
-
|
Maleimide-PEG-Hydroxy (MW 2000)
|
Biochemical Assay Reagents
|
Others
|
|
Mal-PEG-OH (MW 2000) can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.
|
-
- HY-D1005A19
-
|
PEG-PPG-PEG, 4950 (Averag)
|
Biochemical Assay Reagents
Bacterial
|
Infection
|
|
Poloxamer 333 P103 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 4950. Poloxamer 333 P103 exhibits antimicrobial activity, that inihibits 90% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 333 P103 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A4
-
|
PEG-PPG-PEG, 1630 (Averag)
|
Biochemical Assay Reagents
Bacterial
|
Infection
|
|
Poloxamer 122 L42 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1630. Poloxamer 122 L42 exhibits antimicrobial activity, that inihibits 56% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 122 L42 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A8
-
|
PEG-PPG-PEG, 2000 (Averag)
|
Biochemical Assay Reagents
Bacterial
|
Infection
|
|
Poloxamer 181 L61 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2000. Poloxamer 181 L61 exhibits antimicrobial activity, that inihibits 91% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 181 L61 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A9
-
|
PEG-PPG-PEG, 2650 (Averag)
|
Biochemical Assay Reagents
Bacterial
|
Infection
|
|
Poloxamer 183 L63 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2650. Poloxamer 183 L63 exhibits antimicrobial activity, that inihibits 83% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 183 L63 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-15582
-
|
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
|
-
- HY-W087964
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Dodecanedioyl dichloride, Dodecanedioyl dichloride is commonly used in organic synthesis as a general building block for the preparation of various polymers and plastics, including nylon 12 and polyester resins, it can be used to introduce acid chloride groups into other organic molecules, which can then be further reaction to form more complex compounds, moreover, it has been used in medicinal chemistry as a starting material for the synthesis of various drugs and drug candidates.
|
-
- HY-147768
-
|
|
PI3K
Akt
Microtubule/Tubulin
MMP
Apoptosis
|
Cancer
|
|
PI3K/AKT-IN-2 (Compound 12c) is a PI3K and AKT inhibitor. PI3K/AKT-IN-2 blocks the epithelial-mesenchymal transition (EMT) and induces apoptosis. PI3K/AKT-IN-2 inhibits the polymerization of tubulin .
|
-
- HY-B0294
-
|
|
Parasite
Microtubule/Tubulin
STAT
MDM-2/p53
Apoptosis
Autophagy
|
Infection
Cancer
|
|
Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .
|
-
- HY-D1005A6
-
|
PEG-PPG-PEG, 2200 (Averag)
|
Biochemical Assay Reagents
|
Others
|
|
Poloxamer 124 L44 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2200. Poloxamer 124 L44 reveals toxicity with an oral LD50 of 5 g/kg in albino rats. Poloxamer 124 L44 causes ocular irritation. Poloxamer 124 L44 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A21
-
|
PEG-PPG-PEG, 6500 (Averag)
|
Biochemical Assay Reagents
Bacterial
|
Infection
|
|
Poloxamer 335 P105 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 6500. Poloxamer 335 P105 exhibits antimicrobial activity, that inihibits 86% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 334 P104 exhibits muscular toxicity. Poloxamer 334 P104 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-149578
-
|
|
Microtubule/Tubulin
HDAC
|
Cancer
|
|
Tubulin/HDAC-IN-3 (compound 12a) is a potent tubulin/HDAC dual inhibitor. Tubulin/HDAC-IN-3 effectively disrupts tubulin polymerization (IC50: 5.4 μM). Tubulin/HDAC-IN-3 exhibits potent HDAC1/8 inhibitory activities, with IC50 values of 0.155 and 0.177 μM, respectively. Tubulin/HDAC-IN-3 works through blocking cellular cycle, inducing apoptosis and inhibiting colony formation .
|
-
- HY-125527S
-
|
RvD1-d5
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Resolvin D1-d5 is the deuterium labeled Resolvin D1. Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages[1][2].
|
-
- HY-D1005A10
-
|
PEG-PPG-PEG, 2900 (Averag)
|
Biochemical Assay Reagents
Bacterial
|
Infection
Inflammation/Immunology
|
|
Poloxamer 184 L64 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2900. Poloxamer 184 L64 exhibts short-term dermal toxicity characterized by slight erythema and intradermal inflammatory response. Poloxamer 184 L64 exhibits antimicrobial activity, that inihibits 60% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 184 L64 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-B0294R
-
|
|
Parasite
Microtubule/Tubulin
STAT
MDM-2/p53
Apoptosis
Autophagy
|
Infection
Cancer
|
|
Flubendazole (Standard) is the analytical standard of Flubendazole. This product is intended for research and analytical applications. Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D1005A2
-
|
PEG-PPG-PEG, 1900 (Averag)
|
Co-solvents
|
|
Poloxamer 105 L35 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1900. Poloxamer 105 L35 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A25
-
|
PEG-PPG-PEG, 5750 (Averag)
|
Co-solvents
|
|
Poloxamer 403 P123 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 5750. Poloxamer 403 P123 exhibits muscular toxicity .
|
-
- HY-D1005A18
-
|
PEG-PPG-PEG, 13000 (Averag)
|
Co-solvents
|
|
Poloxamer 288 F98 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 13000. Poloxamer 288 F98 reduces the aggregation of red blood cells .
|
-
- HY-D1005A14
-
|
PEG-PPG-PEG, 6600 (Averag)
|
Co-solvents
|
|
Poloxamer 217 F77 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 6600. Poloxamer 217 F77 inhibits proliferation of human lymphocyte cell IIBR1 .
|
-
- HY-D1005A23
-
|
PEG-PPG-PEG, 4400 (Averag)
|
Co-solvents
|
|
Poloxamer 401 L121 is block polymer of polyoxyethylene and polyoxypropylene. Poloxamer 401 L121 is utilized as lymphotrophic particles in nanoparticle engineering, as inhibitor of multidrug resistance and adjuvant activities or as surfactants and emulsifying agents in cosmetics .
|
-
- HY-D1005A1
-
|
PEG-PPG-PEG, 1100 (Averag)
|
Co-solvents
|
|
Poloxamer 101 L31 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1100. Poloxamer 101 L31 forms hydrogel, that is utilized as surfactants and emulsifying agents. Poloxamer 101 L31 induces slight alveolitis .
|
-
- HY-D1005A11
-
|
PEG-PPG-PEG, 3400 (Averag)
|
Co-solvents
|
|
Poloxamer 185 P65 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 3400. Poloxamer 185 P65 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A12
-
|
PEG-PPG-PEG, 2750 (Averag)
|
Co-solvents
|
|
Poloxamer 212 L72 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2750. Poloxamer 212 L72 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A13
-
|
PEG-PPG-PEG, 4150 (Averag)
|
Co-solvents
|
|
Poloxamer 215 P75 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 4150. Poloxamer 215 P75 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A15
-
|
PEG-PPG-PEG, 4200 (Averag)
|
Co-solvents
|
|
Poloxamer 234 P84 is is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 4200. Poloxamer 234 P84 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A20
-
|
PEG-PPG-PEG, 5900 (Averag)
|
Co-solvents
|
|
Poloxamer 334 P104 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 5900. Poloxamer 334 P104 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A5
-
|
PEG-PPG-PEG, 1850 (Averag)
|
Co-solvents
|
|
Poloxamer 123 L43 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1850. Poloxamer 123 L43 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-D1005A7
-
|
PEG-PPG-PEG, 2400 (Averag)
|
Co-solvents
|
|
Poloxamer 125 L45 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2400. Poloxamer 125 L45 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
-
- HY-W013827
-
|
1,4:3,6-Dianhydromannitol
|
Carbohydrates
|
|
Isomannide (1,4:3,6-Dianhydromannitol) is a common intermediate compound that is a derivative of Isosorbide. Isomannide may be used as monomers and building blocks in novel polymers and functional materials, novel organic solvents, medical and pharmaceutical applications, and even as a fuel or fuel additive .
|
-
- HY-167342
-
|
|
Drug Delivery
|
|
PLLA5000-PEG4000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG4000-PLLA5000 can be used in drug delivery research .
|
-
- HY-167343
-
|
|
Drug Delivery
|
|
PLLA5000-PEG3000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG3000-PLLA5000 can be used in drug delivery research .
|
-
- HY-167344
-
|
|
Drug Delivery
|
|
PLLA5000-PEG2000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG2000-PLLA5000 can be used in drug delivery research .
|
-
- HY-167345
-
|
|
Drug Delivery
|
|
PLLA5000-PEG1000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG1000-PLLA5000 can be used in drug delivery research .
|
-
- HY-167346
-
|
|
Drug Delivery
|
|
PLLA4000-PEG8000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG8000-PLLA4000 can be used in drug delivery research .
|
-
- HY-167347
-
|
|
Drug Delivery
|
|
PLLA4000-PEG6000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG6000-PLLA4000 can be used in drug delivery research .
|
-
- HY-167348
-
|
|
Drug Delivery
|
|
PLLA4000-PEG4000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG4000-PLLA4000 can be used in drug delivery research .
|
-
- HY-167349
-
|
|
Drug Delivery
|
|
PLLA4000-PEG3000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG3000-PLLA4000 can be used in drug delivery research .
|
-
- HY-167350
-
|
|
Drug Delivery
|
|
PLLA4000-PEG2000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG2000-PLLA4000 can be used in drug delivery research .
|
-
- HY-167351
-
|
|
Drug Delivery
|
|
PLLA4000-PEG1000-PLLA4000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA4000-PEG1000-PLLA4000 can be used in drug delivery research .
|
-
- HY-167352
-
|
|
Drug Delivery
|
|
PLLA3000-PEG8000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG8000-PLLA3000 can be used in drug delivery research .
|
-
- HY-167353
-
|
|
Drug Delivery
|
|
PLLA3000-PEG6000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG6000-PLLA3000 can be used in drug delivery research .
|
-
- HY-167354
-
|
|
Drug Delivery
|
|
PLLA3000-PEG4000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG4000-PLLA3000 can be used in drug delivery research .
|
-
- HY-167355
-
|
|
Drug Delivery
|
|
PLLA3000-PEG3000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG3000-PLLA3000 can be used in drug delivery research .
|
-
- HY-167356
-
|
|
Drug Delivery
|
|
PLLA3000-PEG2000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG2000-PLLA3000 can be used in drug delivery research .
|
-
- HY-167357
-
|
|
Drug Delivery
|
|
PLLA3000-PEG1000-PLLA3000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA3000-PEG1000-PLLA3000 can be used in drug delivery research .
|
-
- HY-167358
-
|
|
Drug Delivery
|
|
PLLA2000-PEG8000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG8000-PLLA2000 can be used in drug delivery research .
|
-
- HY-167359
-
|
|
Drug Delivery
|
|
PLLA2000-PEG6000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG6000-PLLA2000 can be used in drug delivery research .
|
-
- HY-167360
-
|
|
Drug Delivery
|
|
PLLA2000-PEG4000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG4000-PLLA2000 can be used in drug delivery research .
|
-
- HY-167361
-
|
|
Drug Delivery
|
|
PLLA2000-PEG3000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG3000-PLLA2000 can be used in drug delivery research .
|
-
- HY-167362
-
|
|
Drug Delivery
|
|
PLLA2000-PEG2000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG2000-PLLA2000 can be used in drug delivery research .
|
-
- HY-167363
-
|
|
Drug Delivery
|
|
PLLA2000-PEG1000-PLLA2000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA2000-PEG1000-PLLA2000 can be used in drug delivery research .
|
-
- HY-167364
-
|
|
Drug Delivery
|
|
PLLA1000-PEG8000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG8000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167365
-
|
|
Drug Delivery
|
|
PLLA1000-PEG6000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG6000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167366
-
|
|
Drug Delivery
|
|
PLLA1000-PEG4000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG4000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167367
-
|
|
Drug Delivery
|
|
PLLA1000-PEG3000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG3000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167368
-
|
|
Drug Delivery
|
|
PLLA1000-PEG2000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG2000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167369
-
|
|
Drug Delivery
|
|
PLLA1000-PEG1000-PLLA1000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA1000-PEG1000-PLLA1000 can be used in drug delivery research .
|
-
- HY-167119
-
|
|
Drug Delivery
|
|
PLLA5000-PEG8000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG8000-PLLA5000 can be used in drug delivery research .
|
-
- HY-167140
-
|
|
Drug Delivery
|
|
PLLA6000-PEG8000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG8000-PLLA6000 can be used in drug delivery research .
|
-
- HY-167137
-
|
|
Drug Delivery
|
|
PLLA6000-PEG6000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG6000-PLLA6000 can be used in drug delivery research .
|
-
- HY-167126
-
|
|
Drug Delivery
|
|
PLLA6000-PEG3000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG3000-PLLA6000 can be used in drug delivery research .
|
-
- HY-167128
-
|
|
Drug Delivery
|
|
PLLA8000-PEG8000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG8000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167130
-
|
|
Drug Delivery
|
|
PLLA8000-PEG6000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG6000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167136
-
|
|
Drug Delivery
|
|
PLLA8000-PEG3000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG3000-PLLA8000 can be used in drug delivery research .
|
-
- HY-167134
-
|
|
Drug Delivery
|
|
PLLA8000-PEG4000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG4000-PLLA8000 can be used in drug delivery research .
|
- HY-167132
-
|
|
Drug Delivery
|
|
PLLA6000-PEG4000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG4000-PLLA6000 can be used in drug delivery research .
|
- HY-167138
-
|
|
Drug Delivery
|
|
PLLA8000-PEG2000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG2000-PLLA8000 can be used in drug delivery research .
|
- HY-167139
-
|
|
Drug Delivery
|
|
PLLA8000-PEG1000-PLLA8000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA8000-PEG1000-PLLA8000 can be used in drug delivery research .
|
- HY-167120
-
|
|
Drug Delivery
|
|
PLLA6000-PEG1000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG1000-PLLA6000 can be used in drug delivery research .
|
- HY-167118
-
|
|
Drug Delivery
|
|
PLLA5000-PEG6000-PLLA5000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA5000-PEG6000-PLLA5000 can be used in drug delivery research .
|
- HY-167124
-
|
|
Drug Delivery
|
|
PLLA6000-PEG2000-PLLA6000 is an amphiphilic triblock polymer based on polylactic acid derivatives that improves the specificity and cell affinity of PLA-based biomaterials. PLLA6000-PEG2000-PLLA6000 can be used in drug delivery research .
|
- HY-D1005A16
-
|
PEG-PPG-PEG, 4600 (Averag)
|
Co-solvents
|
|
Poloxamer 235 P85 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 4600. Poloxamer 235 P85 exhibits acute and subchronic toxicity in albino rats with an oral LD50 of >34.6 g/kg. Poloxamer 235 P85 induces ocular irritation in rabbits .
|
- HY-D1005A17
-
|
PEG-PPG-PEG, 11400 (Averag)
|
Co-solvents
|
|
Poloxamer 238 F88 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 11400. Poloxamer 238 F88 reduces the aggregation of red blood cells. Poloxamer 238 F88 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
- HY-D1005A22
-
|
PEG-PPG-PEG, 14600 (Averag)
|
Co-solvents
|
|
Poloxamer 338 F108 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 14600. Poloxamer 338 F108 reduces the aggregation of red blood cells, inhibits proliferation of human lymphocyte cell IIBR1. Poloxamer 338 F108 exhibits short-term and subchronic toxicity in rats .
|
- HY-155902B
-
|
Maleimide-PEG-Hydroxy (MW 1000)
|
Drug Delivery
|
|
Mal-PEG-OH (MW 1000) was used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.
|
- HY-155902
-
|
Maleimide-PEG-Hydroxy (MW 5000)
|
Drug Delivery
|
|
Mal-PEG-OH (MW 5000) can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.
|
- HY-155902A
-
|
Maleimide-PEG-Hydroxy (MW 2000)
|
Drug Delivery
|
|
Mal-PEG-OH (MW 2000) can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.
|
- HY-D1005A19
-
|
PEG-PPG-PEG, 4950 (Averag)
|
Co-solvents
|
|
Poloxamer 333 P103 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 4950. Poloxamer 333 P103 exhibits antimicrobial activity, that inihibits 90% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 333 P103 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
- HY-D1005A4
-
|
PEG-PPG-PEG, 1630 (Averag)
|
Co-solvents
|
|
Poloxamer 122 L42 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 1630. Poloxamer 122 L42 exhibits antimicrobial activity, that inihibits 56% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 122 L42 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
- HY-D1005A8
-
|
PEG-PPG-PEG, 2000 (Averag)
|
Co-solvents
|
|
Poloxamer 181 L61 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2000. Poloxamer 181 L61 exhibits antimicrobial activity, that inihibits 91% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 181 L61 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
- HY-D1005A9
-
|
PEG-PPG-PEG, 2650 (Averag)
|
Co-solvents
|
|
Poloxamer 183 L63 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2650. Poloxamer 183 L63 exhibits antimicrobial activity, that inihibits 83% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 183 L63 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
- HY-W087964
-
|
|
Biochemical Assay Reagents
|
|
Dodecanedioyl dichloride, Dodecanedioyl dichloride is commonly used in organic synthesis as a general building block for the preparation of various polymers and plastics, including nylon 12 and polyester resins, it can be used to introduce acid chloride groups into other organic molecules, which can then be further reaction to form more complex compounds, moreover, it has been used in medicinal chemistry as a starting material for the synthesis of various drugs and drug candidates.
|
- HY-D1005A6
-
|
PEG-PPG-PEG, 2200 (Averag)
|
Co-solvents
|
|
Poloxamer 124 L44 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2200. Poloxamer 124 L44 reveals toxicity with an oral LD50 of 5 g/kg in albino rats. Poloxamer 124 L44 causes ocular irritation. Poloxamer 124 L44 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
- HY-D1005A21
-
|
PEG-PPG-PEG, 6500 (Averag)
|
Co-solvents
|
|
Poloxamer 335 P105 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 6500. Poloxamer 335 P105 exhibits antimicrobial activity, that inihibits 86% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 334 P104 exhibits muscular toxicity. Poloxamer 334 P104 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
- HY-D1005A10
-
|
PEG-PPG-PEG, 2900 (Averag)
|
Co-solvents
|
|
Poloxamer 184 L64 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 2900. Poloxamer 184 L64 exhibts short-term dermal toxicity characterized by slight erythema and intradermal inflammatory response. Poloxamer 184 L64 exhibits antimicrobial activity, that inihibits 60% Mycobacterium avium complex at concentration of 1 mg/mL. Poloxamer 184 L64 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-125527S
-
|
|
|
Resolvin D1-d5 is the deuterium labeled Resolvin D1. Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages[1][2].
|
-
-
- HY-Y0479S3
-
|
|
|
L-Lactic acid-2- 13C1 is the 13C-labeled L-Lactic acid. L-Lactic acid is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid.
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-W250580
-
|
|
|
Others
|
|
Dimethicone is an orally active biochemical assay reagents consisting of a fully methylated linear siloxane polymer whose ends are blocked by trimethylsiloxane units. Dimethicone can lubricate hair and physically block the respiratory system of lice to remove lice. Dimethicone has potential applications in cosmetics and daily cleaning products .
|
-
- HY-155902B
-
|
Maleimide-PEG-Hydroxy (MW 1000)
|
|
Polymers
|
|
Mal-PEG-OH (MW 1000) was used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.
|
-
- HY-155902
-
|
Maleimide-PEG-Hydroxy (MW 5000)
|
|
Polymers
|
|
Mal-PEG-OH (MW 5000) can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.
|
-
- HY-155902A
-
|
Maleimide-PEG-Hydroxy (MW 2000)
|
|
Polymers
|
|
Mal-PEG-OH (MW 2000) can be used as a macroinitiator to obtain amphiphilic diblock copolymers by ring-opening polymerization of LA. Nanoparticles prepared using amphiphilic block copolymers can form active drug delivery systems. Nanoparticles encapsulate Triptolide (HY-32735), which can avoid the disadvantage of Triptolide’s poor water solubility and reduce its toxicity.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
